<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39336845</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Platelet Pathogen Reduction Technology-Should We Stay or Should We Go…?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5359</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13185359</ELocationID><Abstract><AbstractText>The recent COVID-19 pandemic has significantly challenged blood transfusion services (BTS) for providing blood products and for keeping blood supplies available. The possibility that a similar pandemic event may occur again has induced researchers and transfusionists to investigate the adoption of new tools to prevent and reduce these risks. Similarly, increased donor travelling and globalization, with consequent donor deferral and donor pool reduction, have contributed to raising awareness on this topic. Although recent studies have validated the use of pathogen reduction technology (PRT) for the control of transfusion-transmitted infections (TTI) this method is not a standard of care despite increasing adoption. We present a critical commentary on the role of PRT for platelets and on associated problems for blood transfusion services (BTS). The balance of the cost effectiveness of adopting PRT is also discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Piccin</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2645-8496</Identifier><AffiliationInfo><Affiliation>Northern Ireland Blood Transfusion Service (NIBTS), Belfast BT9 7TS, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine V, Medical University of Innsbruck, 6020 Innsbruck, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Industrial Engineering, University of Trento, 38122 Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allameddine</LastName><ForeName>Allameddine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Northern Ireland Blood Transfusion Service (NIBTS), Belfast BT9 7TS, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spizzo</LastName><ForeName>Gilbert</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Oncology, Brixen Hospital, 39042 Bolzano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lappin</LastName><ForeName>Katrina M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0002-6463-5430</Identifier><AffiliationInfo><Affiliation>Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast BT7 1NN, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prati</LastName><ForeName>Daniele</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Servizio Trasfusionale, Ospedale Ca' Granda, 20122 Milano, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">INTERCEPT®</Keyword><Keyword MajorTopicYN="N">MIRASOL®</Keyword><Keyword MajorTopicYN="N">TA-GvHD</Keyword><Keyword MajorTopicYN="N">THERAFLEX®</Keyword><Keyword MajorTopicYN="N">amotosalen</Keyword><Keyword MajorTopicYN="N">bacterial contaminations</Keyword><Keyword MajorTopicYN="N">irradiation</Keyword><Keyword MajorTopicYN="N">platelets</Keyword><Keyword MajorTopicYN="N">riboflavin</Keyword></KeywordList><CoiStatement>D.P. has received travel and research grants, speaking fees, and teaching fees from Diasorin, Diamed, Diatech Pharmacogenetics, Grifols, Immucor, Macopharma, Ortho Clinical Diagnostics, Terumo, Cerus. All authors have no conflicts of interest or any potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39336845</ArticleId><ArticleId IdType="pmc">PMC11432127</ArticleId><ArticleId IdType="doi">10.3390/jcm13185359</ArticleId><ArticleId IdType="pii">jcm13185359</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ainley L.I., Hewitt P.E. Haematology patients and the risk of transfusion transmitted infection. Br. J. Haematol. 2018;180:473–483. doi: 10.1111/bjh.15030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.15030</ArticleId><ArticleId IdType="pubmed">29363748</ArticleId></ArticleIdList></Reference><Reference><Citation>White S.K., Schmidt R.L., Walker B.S., Metcalf R.A. Bacterial contamination rate of platelet components by primary culture: A systematic review and meta-analysis. Transfusion. 2020;60:986–996. doi: 10.1111/trf.15762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.15762</ArticleId><ArticleId IdType="pubmed">32181889</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong H.W.X., Lazarus H.M., Good C.E., Maitta R.W., Jacobs M.R. Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood. 2016;127:496–502. doi: 10.1182/blood-2015-07-655944.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-07-655944</ArticleId><ArticleId IdType="pubmed">26598718</ArticleId></ArticleIdList></Reference><Reference><Citation>Brailsford S.R., Tossell J., Morrison R., McDonald C.P., Pitt T.L. Failure of bacterial screening to detect Staphylococcus aureus: The English experience of donor follow-up. Vox Sang. 2018;113:540–546. doi: 10.1111/vox.12670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12670</ArticleId><ArticleId IdType="pubmed">29799121</ArticleId></ArticleIdList></Reference><Reference><Citation>Corean J., White S.K., Schmidt R.L., Walker B.S., Fisher M.A., Metcalf R.A. Platelet Component False Positive Detection Rate in Aerobic and Anaerobic Primary Culture: A Systematic Review and Meta-Analysis. Transfus. Med. Rev. 2021;35:44–52. doi: 10.1016/j.tmrv.2021.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmrv.2021.05.001</ArticleId><ArticleId IdType="pubmed">34158212</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicchetti A., Coretti S., Sacco F., Rebulla P., Fiore A., Rumi F., Di Bidino R., Urbina L.I., Refolo P., Sacchini D., et al. Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system. Blood Transfus. 2018;16:483–489.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6214822</ArticleId><ArticleId IdType="pubmed">30201081</ArticleId></ArticleIdList></Reference><Reference><Citation>Giménez-Richarte A., Ortiz de Salazar M.I., Giménez-Richarte M., Larrea L., Arbona C., Marco P., Ramos-Rincón J.M. Pathogen inactivation methods to prevent transfusion-transmissible arboviruses: A systematic review and meta-analysis. Trop. Med. Int. Health. 2023;28:262–274. doi: 10.1111/tmi.13863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tmi.13863</ArticleId><ArticleId IdType="pubmed">36806816</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein H.G., Dodd R.Y., Dzik W.H., Luban N.L., Ness P.M., Pisciotto P., Schiff P.D., Snyder E.L. Current status of solvent/detergent-treated frozen plasma. Transfusion. 1998;38:102–107. doi: 10.1046/j.1537-2995.1998.38198141508.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1537-2995.1998.38198141508.x</ArticleId><ArticleId IdType="pubmed">9482404</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebulla P., Prati D. Pathogen reduction for platelets-a review of recent implementation strategies. Pathogens. 2022;11:142. doi: 10.3390/pathogens11020142.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11020142</ArticleId><ArticleId IdType="pmc">PMC8879285</ArticleId><ArticleId IdType="pubmed">35215085</ArticleId></ArticleIdList></Reference><Reference><Citation>Gathof B.S., Tauszig M.E., Picker S.M. Pathogen inactivation/reduction of platelet concentrates: Turning theory into practice. ISBT Sci. Ser. 2010;5:114–119. doi: 10.1111/j.1751-2824.2010.01417.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1751-2824.2010.01417.x</ArticleId><ArticleId IdType="pmc">PMC7169244</ArticleId><ArticleId IdType="pubmed">32328165</ArticleId></ArticleIdList></Reference><Reference><Citation>Guide to the Preparation, Use and Quality Assurance of Blood Components. European Committee EDQM. 21th Edition 2023.  [(accessed on 15 August 2024)].  Available online:  https://freepub.edqm.eu/publications/AUTOPUB_48/detail.</Citation></Reference><Reference><Citation>McCullough J., Goldfinger D., Gorlin J., Riley W.J., Sandhu H., Stowell C., Ward D., Clay M., Pulkrabek S., Chrebtow V., et al. Cost implications of implementation of pathogen-inactivated platelets. Transfusion. 2015;55:2312–2320. doi: 10.1111/trf.13149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.13149</ArticleId><ArticleId IdType="pmc">PMC4691315</ArticleId><ArticleId IdType="pubmed">25989465</ArticleId></ArticleIdList></Reference><Reference><Citation>Cid J., Escolar G., Lozano M. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: Results of a meta-analysis of randomized controlled trials. Vox Sang. 2012;103:322–330. doi: 10.1111/j.1423-0410.2012.01614.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1423-0410.2012.01614.x</ArticleId><ArticleId IdType="pubmed">22563850</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerkhoffs J.L.H., van Putten W.L.J., Novotny V.M.J., Te Boekhorst P.A.W., Schipperus M.R., Zwaginga J.J., van Pampus L.C.M., de Greef G.E., Luten M., Huijgens P.C., et al. Dutch-Belgian HOVON cooperative group. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br. J. Haematol. 2010;150:209–217. doi: 10.1111/j.1365-2141.2010.08227.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2010.08227.x</ArticleId><ArticleId IdType="pubmed">20507310</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro G., Merkel P.A., Giclas H.E., Gibula A., Andersen G.E., Corash L.M., Lin J.S., Green J., Knight V., Stassinopoulos A. Amotosalen/UVA treatment inactivates T cells more effectively than the recommended gamma dose for prevention of transfusion-associated graft-versus-host disease. Transfusion. 2018;58:1506–1515. doi: 10.1111/trf.14589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.14589</ArticleId><ArticleId IdType="pubmed">29607502</ArticleId></ArticleIdList></Reference><Reference><Citation>Lozano M., Knutson F., Tardivel R., Cid J., Maymó R.M., Löf H., Roddie H., Pelly J., Docherty A., Sherman C., et al. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion. Br. J. Haematol. 2011;153:393–401. doi: 10.1111/j.1365-2141.2011.08635.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2011.08635.x</ArticleId><ArticleId IdType="pubmed">21418180</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasirye R., Hume H.A., Bloch E.M., Lubega I., Kyeyune D., Shrestha R., Ddungu H., Musana H.W., Dhabangi A., Ouma J., et al. The Mirasol Evaluation of Reduction in Infections Trial (MERIT): Study protocol for a randomized controlled clinical trial. Trials. 2022;23:257. doi: 10.1186/s13063-022-06137-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-022-06137-8</ArticleId><ArticleId IdType="pmc">PMC8978156</ArticleId><ArticleId IdType="pubmed">35379302</ArticleId></ArticleIdList></Reference><Reference><Citation>Allain J.P., Owusu-Ofori A.K., Assennato S.M., Marschner S., Goodrich R.P., Owusu-Ofori S. Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: The African Investigation of the Mirasol System (AIMS) randomised controlled trial. Lancet. 2016;387:1753–1761. doi: 10.1016/S0140-6736(16)00581-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)00581-X</ArticleId><ArticleId IdType="pubmed">27116282</ArticleId></ArticleIdList></Reference><Reference><Citation>Ojea A.M., Seco C., Mata P., Muñoz M.D.C., Álvarez Argüelles M.E., Rodríguez-Frías F., Quer Sivila J., Rando Segura A., García-Gala J.M., Rodriguez M. Transfusion-transmission of hepatitis E virus through red blood cell transfusion but not through platelet concentrates: A case report from Spain. Transfusion. 2023;63:1767–1772. doi: 10.1111/trf.17498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.17498</ArticleId><ArticleId IdType="pubmed">37593971</ArticleId></ArticleIdList></Reference><Reference><Citation>Owada T., Kaneko M., Matsumoto C., Sobata R., Igarashi M., Suzuki K., Matsubayashi K., Mio K., Uchida S., Satake M., et al. Establishment of culture systems for Genotypes 3 and 4 hepatitis E virus (HEV) obtained from human blood and application of HEV inactivation using a pathogen reduction technology system. Transfusion. 2014;54:2820–2827. doi: 10.1111/trf.12686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.12686</ArticleId><ArticleId IdType="pubmed">24845192</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez-Marco T., Garcia-Recio M., Girona-Llobera E. Our experience in riboflavin and ultraviolet light pathogen reduction technology for platelets: From platelet production to patient care. Transfusion. 2018;58:1881–1889. doi: 10.1111/trf.14797.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.14797</ArticleId><ArticleId IdType="pubmed">30132911</ArticleId></ArticleIdList></Reference><Reference><Citation>Koepsell S.A., Stolla M., Sedjo R.L., Carson J., Knudson M., Cook R., Fasano R., Ngamsuntikul S.G., Cohn C., Gorlin J., et al. Results of clinical effectiveness of conventional versus Mirasol-treated Apheresis Platelets in Patients with Hypoproliferative Thrombocytopenia (MiPLATE) trial. Transfusion. 2024;64:457–465. doi: 10.1111/trf.17720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.17720</ArticleId><ArticleId IdType="pubmed">38314476</ArticleId></ArticleIdList></Reference><Reference><Citation>Malvaux N., Defraigne F., Bartziali S., Bellora C., Mommaerts K., Betsou F., Schuhmacher A. In Vitro Comparative Study of Platelets Treated with Two Pathogen-Inactivation Methods to Extend Shelf Life to 7 Days. Pathogens. 2022;11:343. doi: 10.3390/pathogens11030343.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11030343</ArticleId><ArticleId IdType="pmc">PMC8949436</ArticleId><ArticleId IdType="pubmed">35335667</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris P.J., Kaidarova Z., Maiorana E., Milani S., Lebedeva M., Busch M.P., Custer B., Rebulla P. Ultraviolet light-based pathogen inactivation and alloimmunization after platelet transfusion: Results from a randomized trial. Transfusion. 2018;58:1210–1217. doi: 10.1111/trf.14534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.14534</ArticleId><ArticleId IdType="pubmed">29473173</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., de Korte D., Woolum M.D., Ruane P.H., Keil S.D., Lockerbie O., McLean R., Goodrich R.P. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: Comparisons with pathogen-reduction technology-treated apheresis platelet products. Vox Sang. 2004;87:82–90. doi: 10.1111/j.1423-0410.2004.00548.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1423-0410.2004.00548.x</ArticleId><ArticleId IdType="pubmed">15355498</ArticleId></ArticleIdList></Reference><Reference><Citation>Escolar G., Diaz-Ricart M., McCullough J. Impact of different pathogen reduction technologies on the biochemistry, function, and clinical effectiveness of platelet concentrates: An updated view during a pandemic. Transfusion. 2022;62:227–246. doi: 10.1111/trf.16747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.16747</ArticleId><ArticleId IdType="pmc">PMC9300014</ArticleId><ArticleId IdType="pubmed">34870335</ArticleId></ArticleIdList></Reference><Reference><Citation>Seltsam A., Müller T.H. UVC Irradiation for Pathogen Reduction of Platelet Concentrates and Plasma. Transfus. Med. Hemother. 2011;38:43–54. doi: 10.1159/000323845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000323845</ArticleId><ArticleId IdType="pmc">PMC3132979</ArticleId><ArticleId IdType="pubmed">21779205</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravemann U., Handke W., Müller T.H., Seltsam A. Bacterial inactivation of platelet concentrates with the THERAFLEX UV-Platelets pathogen inactivation system. Transfusion. 2019;59:1324–1332. doi: 10.1111/trf.15119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.15119</ArticleId><ArticleId IdType="pubmed">30588633</ArticleId></ArticleIdList></Reference><Reference><Citation>Eickmann M., Gravemann U., Handke W., Tolksdorf F., Reichenberg S., Müller T.H., Seltsam A. Inactivation of three emerging viruses—Severe acute respiratory syndrome coronavirus, Crimean–Congo haemorrhagic fever virus and Nipah virus—In platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light. Vox Sang. 2020;115:146–151. doi: 10.1111/vox.12888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12888</ArticleId><ArticleId IdType="pmc">PMC7169309</ArticleId><ArticleId IdType="pubmed">31930543</ArticleId></ArticleIdList></Reference><Reference><Citation>Praditya D., Friesland M., Gravemann U., Handke W., Todt D., Behrendt P., Müller T.H., Steinmann E., Seltsam A. Hepatitis E virus is effectively inactivated in platelet concentrates by ultraviolet C light. Vox Sang. 2020;115:555–561. doi: 10.1111/vox.12936.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12936</ArticleId><ArticleId IdType="pubmed">32383163</ArticleId></ArticleIdList></Reference><Reference><Citation>Brixner V., Bug G., Pohler P., Krämer D., Metzner B., Voss A., Casper J., Ritter U., Klein S., Alakel N., et al. Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: A randomized controlled non-inferiority trial. Haematologica. 2021;106:1086–1096. doi: 10.3324/haematol.2020.260430.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2020.260430</ArticleId><ArticleId IdType="pmc">PMC8018132</ArticleId><ArticleId IdType="pubmed">33538149</ArticleId></ArticleIdList></Reference><Reference><Citation>Bashir S., Cookson P., Wiltshire M., Hawkins L., Sonoda L., Thomas S., Seltsam A., Tolksdorf F., Williamson L.M., Cardigan R. Pathogen inactivation of platelets using ultraviolet C light: Effect on in vitro function and recovery and survival of platelets. Transfusion. 2013;53:990–1000. doi: 10.1111/j.1537-2995.2012.03854.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2012.03854.x</ArticleId><ArticleId IdType="pubmed">22905813</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulze T.J., Graveman U., Seltsam A. THERAFLEX ultraviolet C (UVC)-based pathogen reduction technology for bacterial inactivation in blood components: Advantages and limitations. Ann. Blood. 2002;7:28. doi: 10.21037/aob-21-44.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/aob-21-44</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez-Arcos S., Evans S., McIntyre T., Pang C., Yi Q.L., DiFranco C., Goldman M. Extension of platelet shelf life with an improved bacterial testing algorithm. Transfusion. 2020;60:2918–2928. doi: 10.1111/trf.16112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.16112</ArticleId><ArticleId IdType="pubmed">33140420</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohlsson S., Diedrich B., Uhlin M., Sandgren P. Optimized processing for pathogen inactivation of double-dose buffy-coat platelet concentrates: Maintained in vitro quality over 7-day storage. Vox Sang. 2018;113:611–621. doi: 10.1111/vox.12696.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12696</ArticleId><ArticleId IdType="pubmed">30156292</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorria C., Labata G., Lezaun M., López F.J., Pérez Aliaga A.I., Pérez Vaquero M.Á. Impact of implementing pathogen reduction technologies for platelets on reducing outdates. Vox Sang. 2020;115:167–173. doi: 10.1111/vox.12860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12860</ArticleId><ArticleId IdType="pubmed">31729059</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitman J.P., Payrat J.M., Park M.S., Liu K., Corash L., Benjamin R.J. Longitudinal analysis of annual national hemovigilance data to assess pathogen reduced platelet transfusion trends during conversion to routine universal clinical use and 7-day storage. Transfusion. 2023;63:711–723. doi: 10.1111/trf.17285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.17285</ArticleId><ArticleId IdType="pubmed">36802055</ArticleId></ArticleIdList></Reference><Reference><Citation>Fast L.D., Dileone G., Li J., Goodrich R. Functional inactivation of white blood cells by Mirasol treatment. Transfusion. 2006;46:642–648. doi: 10.1111/j.1537-2995.2006.00777.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2006.00777.x</ArticleId><ArticleId IdType="pubmed">16584442</ArticleId></ArticleIdList></Reference><Reference><Citation>Corash L., Benjamin R.J. The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: The amotosalen-ultraviolet A pathogen reduction treatment model. Transfusion. 2016;56((Suppl. S1)):S29–S38. doi: 10.1111/trf.13530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.13530</ArticleId><ArticleId IdType="pubmed">27001358</ArticleId></ArticleIdList></Reference><Reference><Citation>Fast L.D., DiLeone G., Marschner S. Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Transfusion. 2011;51:1397–1404. doi: 10.1111/j.1537-2995.2010.02984.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2010.02984.x</ArticleId><ArticleId IdType="pubmed">21155832</ArticleId></ArticleIdList></Reference><Reference><Citation>Sim J., Tsoi W.C., Lee C.K., Leung R., Lam C.C.K., Koontz C., Liu A.Y., Huang N., Benjamin R.J., Vermeij H.J., et al. Transfusion of pathogen-reduced platelet components without leukoreduction. Transfusion. 2019;59:1953–1961. doi: 10.1111/trf.15269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.15269</ArticleId><ArticleId IdType="pmc">PMC6850058</ArticleId><ArticleId IdType="pubmed">30919465</ArticleId></ArticleIdList></Reference><Reference><Citation>Fast L.D. Developments in the prevention of transfusion-associated graft-versus-host disease. Br. J. Haematol. 2012;158:563–568. doi: 10.1111/j.1365-2141.2012.09197.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.2012.09197.x</ArticleId><ArticleId IdType="pubmed">22734439</ArticleId></ArticleIdList></Reference><Reference><Citation>Lieberman L., Devine D.V., Reesink H.W., Panzer S., Wong J., Raison T., Benson S., Pink J., Leitner G.C., Horvath M., et al. Prevention of transfusion-transmitted cytomegalovirus (CMV) infection: Standards of care. Vox Sang. 2014;107:276–311. doi: 10.1111/vox.12103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12103</ArticleId><ArticleId IdType="pubmed">24801438</ArticleId></ArticleIdList></Reference><Reference><Citation>INTERCEPT Platelets, Technical Data Sheet.  [(accessed on 15 August 2024)].  Available online:  https://www.interceptbloodsystem.com/sites/default/files/resources/prd-tds_00121_v10.0_reduced_file_size_-_secured.pdf.</Citation></Reference><Reference><Citation>Lanteri M.C., Santa-Maria F., Laughhunn A., Girard Y.A., Picard-Maureau M., Payrat J.M., Irsch J., Stassinopoulos A., Bringmann P. Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light. Transfusion. 2020;60:1319–1331. doi: 10.1111/trf.15807.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.15807</ArticleId><ArticleId IdType="pmc">PMC7317863</ArticleId><ArticleId IdType="pubmed">32333396</ArticleId></ArticleIdList></Reference><Reference><Citation> [(accessed on 25 August 2024)].  Available online:  https://www.terumobct.com/Public/306690232.pdf.</Citation></Reference><Reference><Citation> [(accessed on 25 August 2024)].  Available online:  https://aob.amegroups.org/article/view/6833/html.</Citation></Reference><Reference><Citation>Castro E., González L.M., Rubio J.M., Ramiro R., Gironés N., Montero E. The efficacy of the ultraviolet C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets. Transfusion. 2014;54:2207–2216. doi: 10.1111/trf.12598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.12598</ArticleId><ArticleId IdType="pubmed">24666393</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravemann U., Boelke M., Könenkamp L., Söder L., Maurer M., Ziegler U., Schulze T.J., Seltsam A., Becker S.C., Steffen I. West Nile and Usutu viruses are efficiently inactivated in platelet concentrates by UVC light using the THERAFLEX UV-Platelets system. Vox Sang. 2024;119:827–833. doi: 10.1111/vox.13648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.13648</ArticleId><ArticleId IdType="pubmed">38699884</ArticleId></ArticleIdList></Reference><Reference><Citation>Coene J., Devreese K., Sabot B., Feys H.B., Vandekerckhove P., Compernolle V. Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction. Transfusion. 2014;54:1321–1331. doi: 10.1111/trf.12460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.12460</ArticleId><ArticleId IdType="pubmed">24472023</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravanat C., Dupuis A., Marpaux N., Naegelen C., Mourey G., Isola H., Laforet M., Morel P., Gachet C. Is the thrombin generation test, a useful research tool, suitable to characterize therapeutic plasma? In Proceedings of the ISTH 2017, Berlin, Germany, 8–13 July 2017;</Citation></Reference><Reference><Citation>Flamholz R., Jeon H.R., Baron J.M., Baron B.W. Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: Is its decreased protein S activity clinically related to their development of deep venous thromboses? J. Clin. Apher. 2000;15:169–172. doi: 10.1002/1098-1101(2000)15:3&lt;169::AID-JCA2&gt;3.0.CO;2-R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1098-1101(2000)15:3&lt;169::AID-JCA2&gt;3.0.CO;2-R</ArticleId><ArticleId IdType="pubmed">10962468</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarranton H., Lawrie A.S., Purdy G., Mackie I.J., Machin S.J. Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus. Med. 2004;14:39–44. doi: 10.1111/j.0958-7578.2004.00478.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0958-7578.2004.00478.x</ArticleId><ArticleId IdType="pubmed">15043592</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellstern P., Solheimb B.G. The Use of Solvent/Detergent Treatment in Pathogen Reduction of Plasma. Transfus. Med. Hemother. 2011;38:65–70. doi: 10.1159/000323552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000323552</ArticleId><ArticleId IdType="pmc">PMC3132981</ArticleId><ArticleId IdType="pubmed">21779207</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccin A., O’Connor-Byrne N., Daves M., Lynch K., Farshbaf A.D., Martin-Loeches I. Autoimmune disease and sickle cell anaemia: ‘Intersecting pathways and differential diagnosis’. Br. J. Haematol. 2022;197:518–528. doi: 10.1111/bjh.18109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.18109</ArticleId><ArticleId IdType="pubmed">35244209</ArticleId></ArticleIdList></Reference><Reference><Citation>Backholer L., Wiltshire M., Proffitt S., Cookson P., Cardigan R. Paired comparison of methylene blue- and amotosalen-treated plasma and cryoprecipitate. Vox Sang. 2016;110:352–361. doi: 10.1111/vox.12368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12368</ArticleId><ArticleId IdType="pubmed">26757252</ArticleId></ArticleIdList></Reference><Reference><Citation>Larrea L., Ortiz-de-Salazar M.I., Martínez P., Roig R. Quantitative analysis of plasma proteins in whole blood-derived fresh frozen plasma prepared with three pathogen reduction technologies. Transfus. Apher. Sci. 2015;52:305–310. doi: 10.1016/j.transci.2015.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2015.01.008</ArticleId><ArticleId IdType="pubmed">25656475</ArticleId></ArticleIdList></Reference><Reference><Citation>Estcourt L.J., Malouf R., Hopewell S., Trivella M., Doree C., Stanworth S.J., Murphy M.F. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst. Rev. 2017;7:CD009072. doi: 10.1002/14651858.CD009072.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD009072.pub3</ArticleId><ArticleId IdType="pmc">PMC5558872</ArticleId><ArticleId IdType="pubmed">28756627</ArticleId></ArticleIdList></Reference><Reference><Citation>Pati I., Masiello F., Pupella S., Cruciani M., De Angelis V. Efficacy and Safety of Pathogen-Reduced Platelets Compared with Standard Apheresis Platelets: A Systematic Review of RCTs. Pathogens. 2022;11:639. doi: 10.3390/pathogens11060639.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens11060639</ArticleId><ArticleId IdType="pmc">PMC9231062</ArticleId><ArticleId IdType="pubmed">35745493</ArticleId></ArticleIdList></Reference><Reference><Citation>Rebulla P., Vaglio S., Beccaria F., Bonfichi M., Carella A., Chiurazzi F., Coluzzi S., Cortelezzi A., Gandini G., Girelli G., et al. Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies. Transfusion. 2017;57:1171–1183. doi: 10.1111/trf.14042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.14042</ArticleId><ArticleId IdType="pubmed">28236335</ArticleId></ArticleIdList></Reference><Reference><Citation>Garban F., Guyard A., Labussière H., Bulabois C.E., Marchand T., Mounier C., Caillot D., Bay J.O., Coiteux V., Schmidt-Tanguy A., et al. Evaluation of the Efficacy of Platelets Treated with Pathogen Reduction Process (EFFIPAP) Study Group. Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients with Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial. JAMA Oncol. 2018;4:468–475.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885167</ArticleId><ArticleId IdType="pubmed">29392283</ArticleId></ArticleIdList></Reference><Reference><Citation>Osselaer J.C., Doyen C., Defoin L., Debry C., Goffaux M., Messe N., Van Hooydonk M., Bosly A., Lin J.S., Lin L., et al. Universal adoption of pathogen inactivation of platelet components: Impact on platelet and red blood cell component use. Transfusion. 2009;49:1412–1422. doi: 10.1111/j.1537-2995.2009.02151.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2009.02151.x</ArticleId><ArticleId IdType="pubmed">19389022</ArticleId></ArticleIdList></Reference><Reference><Citation>Cazenave J.P., Isola H., Waller C., Mendel I., Kientz D., Laforêt M., Raidot J.P., Kandel G., Wiesel M.L., Corash L. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: Impact on patient outcomes and component utilization during a 3-year period. Transfusion. 2011;51:622–629. doi: 10.1111/j.1537-2995.2010.02873.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2010.02873.x</ArticleId><ArticleId IdType="pubmed">20849406</ArticleId></ArticleIdList></Reference><Reference><Citation>Infanti L., Holbro A., Passweg J., Bolliger D., Tsakiris D.A., Merki R., Plattner A., Tappe D., Irsch J., Lin J.S., et al. Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days. Transfusion. 2019;59:3350–3361. doi: 10.1111/trf.15511.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.15511</ArticleId><ArticleId IdType="pmc">PMC6900102</ArticleId><ArticleId IdType="pubmed">31574181</ArticleId></ArticleIdList></Reference><Reference><Citation>Amato M., Schennach H., Astl M., Chen C.Y., Lin J.S., Benjamin R.J., Nussbaumer W. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre. Vox Sang. 2017;112:47–55. doi: 10.1111/vox.12456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12456</ArticleId><ArticleId IdType="pubmed">28001297</ArticleId></ArticleIdList></Reference><Reference><Citation>Nussbaumer W., Amato M., Schennach H., Astl M., Chen C.Y., Lin J.S., Corash L., Benjamin R.J. Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients. Vox Sang. 2017;112:249–256. doi: 10.1111/vox.12489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12489</ArticleId><ArticleId IdType="pubmed">28198023</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullough J., Vesole D.H., Benjamin R.J., Slichter S.J., Pineda A., Snyder E., Stadtmauer E.A., Lopez-Plaza I., Coutre S., Strauss R.G., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT Trial. Blood. 2004;104:1534–1541. doi: 10.1182/blood-2003-12-4443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2003-12-4443</ArticleId><ArticleId IdType="pubmed">15138160</ArticleId></ArticleIdList></Reference><Reference><Citation>Blake J.T., McTaggart K., Couture C. Estimating the impact on the inventory of implementing pathogen-reduced platelets in Canada. Transfusion. 2021;61:3150–3160. doi: 10.1111/trf.16691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.16691</ArticleId><ArticleId IdType="pubmed">34612539</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy S., Snyder E., Cable R., Slichter S.J., Strauss R.G., McCullough J., Lin J., Corash L., Conlan M.G. SPRINT Study Group. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: An analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion. 2006;46:24–33. doi: 10.1111/j.1537-2995.2005.00671.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2005.00671.x</ArticleId><ArticleId IdType="pubmed">16398727</ArticleId></ArticleIdList></Reference><Reference><Citation>Stivala S., Gobbato S., Infanti L., Reiner M.F., Bonetti N., Meyer S.C., Camici G.G., Lüscher T.F., Buser A., Beer J.H. Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance. Haematologica. 2017;102:1650–1660. doi: 10.3324/haematol.2017.164137.</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.2017.164137</ArticleId><ArticleId IdType="pmc">PMC5622849</ArticleId><ArticleId IdType="pubmed">28729303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S., Handke W., Gravemann U., Döscher A., Brixner V., Müller T.H., Seltsam A. Mitochondrial DNA multiplex real-time polymerase chain reaction inhibition assay for quality control of pathogen inactivation by ultraviolet C light in platelet concentrates. Transfusion. 2018;58:758–765. doi: 10.1111/trf.14464.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.14464</ArticleId><ArticleId IdType="pubmed">29282743</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruchmüller I., Lösel R., Bugert P., Corash L., Lin L., Klüter H., Janetzko K. Effect of the psoralen-based photochemical pathogen inactivation on mitochondrial DNA in platelets. Platelets. 2005;16:441–445. doi: 10.1080/09537100500129300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09537100500129300</ArticleId><ArticleId IdType="pubmed">16287610</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakkour S., Chafets D.M., Wen L., Dupuis K., Castro G., Green J.M., Stassinopoulos A., Busch M.P., Lee T.H. Assessment of nucleic acid modification induced by amotosalen and ultraviolet A light treatment of platelets and plasma using real-time polymerase chain reaction amplification of variable length fragments of mitochondrial DNA. Transfusion. 2016;56:410–420. doi: 10.1111/trf.13360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.13360</ArticleId><ArticleId IdType="pubmed">26446053</ArticleId></ArticleIdList></Reference><Reference><Citation>Diallo I., Benmoussa A., Laugier J., Osman A., Hitzler W.E., Provost P. Platelet Pathogen Reduction Technologies Alter the MicroRNA Profile of Platelet-Derived Microparticles. Front. Cardiovasc. Med. 2020;7:31. doi: 10.3389/fcvm.2020.00031.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2020.00031</ArticleId><ArticleId IdType="pmc">PMC7096552</ArticleId><ArticleId IdType="pubmed">32266291</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnason N.A., Johannson F., Landrö R., Hardarsson B., Irsch J., Gudmundsson S., Rolfsson O., Sigurjonsson O.E. Pathogen inactivation with amotosalen plus UVA illumination minimally impacts microRNA expression in platelets during storage under standard blood banking conditions. Transfusion. 2019;59:3727–3735. doi: 10.1111/trf.15575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.15575</ArticleId><ArticleId IdType="pubmed">31674051</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrugia A. Cost of pathogen reduction for platelets: Reply to Cicchetti et al. Blood Transfus 2018; 16: 483-9. Blood Transfus. 2019;17:84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6343600</ArticleId><ArticleId IdType="pubmed">30418132</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrugia A. The Evolution of the Safety of Plasma Products from Pathogen Transmission—A Continuing Narrative. Pathogens. 2023;12:318. doi: 10.3390/pathogens12020318.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens12020318</ArticleId><ArticleId IdType="pmc">PMC9967166</ArticleId><ArticleId IdType="pubmed">36839590</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell C.E., Botteman M.F., Gao X., Weissfeld J.L., Postma M.J., Pashos C.L., Triulzi D., Staginnus U. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin. Ther. 2003;25:2464–2486. doi: 10.1016/S0149-2918(03)80288-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0149-2918(03)80288-6</ArticleId><ArticleId IdType="pmc">PMC7133650</ArticleId><ArticleId IdType="pubmed">14604745</ArticleId></ArticleIdList></Reference><Reference><Citation>Davison N., Willis A. Abstracts of the 31st Regional ISBT Congress, ISBT In Focus, Virtual meeting, 2–8 June 2021. Vox Sang. 2021;116((Suppl. S1)):5–188. doi: 10.1111/vox.13117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.13117</ArticleId><ArticleId IdType="pubmed">34060100</ArticleId></ArticleIdList></Reference><Reference><Citation>Grégoire Y., Delage G., Custer B., Rochette S., Renaud C., Lewin A., Germain M. Cost-effectiveness of pathogen reduction technology for plasma and platelets in Quebec: A focus on potential emerging pathogens. Transfusion. 2022;62:1208–1217. doi: 10.1111/trf.16926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.16926</ArticleId><ArticleId IdType="pubmed">35560238</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosskopf K., Helmberg W., Schlenke P. Pathogen reduction of double-dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects. Transfusion. 2020;60:2058–2066. doi: 10.1111/trf.15926.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.15926</ArticleId><ArticleId IdType="pmc">PMC7540585</ArticleId><ArticleId IdType="pubmed">32619068</ArticleId></ArticleIdList></Reference><Reference><Citation>Keltner N.M., Cushing M.M., Haas T., Spinella P.C. Analyzing and modeling massive transfusion strategies and the role of fibrinogen-How much is the patient actually receiving? Transfusion. 2024;64((Suppl. S2)):S136–S145. doi: 10.1111/trf.17774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.17774</ArticleId><ArticleId IdType="pubmed">38433522</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>